Sugi Predict

Sugi Predict / Targets / RAMP1

RAMP1

Receptor activity-modifying protein 1 (Calcit · O60894 · RAMP1 on Sugi Atlas →

16,858 patent compounds predicted against RAMP1, 12,076 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL846226 SCHEMBL846226 0.51 15/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL837743) 0.51 13/20
SCHEMBL846254 SCHEMBL846254 0.55 12/20
SCHEMBL846704 SCHEMBL846704 0.53 12/20
SCHEMBL836155 SCHEMBL836155 0.49 12/20
SCHEMBL1891441 SCHEMBL1891441 0.57 11/20
SCHEMBL837000 SCHEMBL837000 0.51 11/20
SCHEMBL978391 SCHEMBL978391 0.51 11/20
SCHEMBL978393 SCHEMBL978393 0.51 11/20
SCHEMBL838209 SCHEMBL838209 0.49 11/20
SCHEMBL976476 SCHEMBL976476 0.49 11/20
SCHEMBL977185 SCHEMBL977185 0.49 11/20
SCHEMBL978566 SCHEMBL978566 0.49 11/20
SCHEMBL979404 SCHEMBL979404 0.49 11/20
SCHEMBL978961 SCHEMBL978961 0.69 10/20
SCHEMBL978962 SCHEMBL978962 0.69 10/20
SCHEMBL980309 SCHEMBL980309 0.69 10/20
SCHEMBL980311 SCHEMBL980311 0.69 10/20
SCHEMBL846702 SCHEMBL846702 0.59 10/20
SCHEMBL2066765 SCHEMBL2066765 0.58 10/20

Clinical trials — most relevant to RAMP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD PHASE4UNKNOWN
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury PHASE3COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease PHASE2ACTIVE_NOT_RECRUITING
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications PHASE1UNKNOWN
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A EARLY_PHASE1COMPLETED
D-aspartate and Therapeutic Exercise EARLY_PHASE1UNKNOWN
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure nanUNKNOWN
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies nanCOMPLETED
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments nanRECRUITING
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia. nanCOMPLETED
Evaluating the Role of Pre-existing Resolvins in the Resolution of ICU Delirium nanWITHDRAWN
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers nanUNKNOWN
Patient Controlled Analgesia Pharmacogenetic Study nanCOMPLETED
Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain nanCOMPLETED
MOR-1 Expression in Colorectal Cancer and Disease-free Survival Relationship. Five-year Follow-up. nanCOMPLETED
Longitudinal Assessment of Iron Rims in MS Lesions nanRECRUITING
Genetic Polymorphisms Associated With CAD nanUNKNOWN
Genetic Architecture of Chronic Inflammatory Demyelinating Polyradiculoneuropathy nanUNKNOWN
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
Glucagon Like Peptide-1 in Remote Ischemic Conditioning nanCOMPLETED
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry Bad Cholesterol in the Blood nanCOMPLETED
Probiotics and Systemic Inflammation in Patients With Metabolic Syndrome and High Cardiovascular Risk nanWITHDRAWN
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RAMP1 binder may also engage these)

ProteinNameSimilarity
Q9WTJ5 — 0.997 Q9WTJ5 →
Q8R4C6 — 0.997 Q8R4C6 →
Q9JJ74 — 0.991 Q9JJ74 →
Q867C0 — 0.990 Q867C0 →
Q8R4C5 — 0.979 Q8R4C5 →
RAMP2 Receptor activity-modifying protein 2 (Calcit 0.977 landscape →
Q9JHJ1 — 0.973 Q9JHJ1 →
Q9WUP0 — 0.968 Q9WUP0 →
Q8R4C4 — 0.967 Q8R4C4 →
A7MBM2 — 0.964 A7MBM2 →
Q8BGT0 — 0.964 Q8BGT0 →
Q6ZVN8 — 0.964 Q6ZVN8 →
Q8BND5 — 0.964 Q8BND5 →
Q9WUP1 — 0.963 Q9WUP1 →
Q80YF6 — 0.963 Q80YF6 →
W5XKT8 — 0.962 W5XKT8 →
Q8N7M5 — 0.962 Q8N7M5 →
Q8IU54 — 0.962 Q8IU54 →
Q4VK74 — 0.962 Q4VK74 →
Q9C0H2 — 0.961 Q9C0H2 →
Q5FVL3 — 0.961 Q5FVL3 →
Q96PE1 — 0.961 Q96PE1 →
Q96F46 — 0.961 Q96F46 →
O76095 — 0.961 O76095 →
P17491 — 0.961 P17491 →
Q6PRD1 — 0.961 Q6PRD1 →
Q16586 — 0.961 Q16586 →
O08542 — 0.961 O08542 →
ATP6AP1 V-type proton ATPase subunit S1 0.961 landscape →
Q99ML4 — 0.960 Q99ML4 →